|
|
Blood, 1 May 2007, Vol. 109, No. 9, pp. 4038-4044.
Prepublished online as a Blood First Edition Paper on January 11, 2007; DOI 10.1182/blood-2006-10-051755.
 Previous Article | Table of Contents | Next Article 
RED CELLS
Hepcidin antimicrobial peptide transgenic mice exhibit features of the anemia of inflammation
Cindy N. Roy1,3,
Howard H. Mak1,
Imo Akpan1,
Grigoriy Losyev1,
David Zurakowski2, and
Nancy C. Andrews1,3
1 Division of Hematology/Oncology, Children's Hospital Boston, Boston, MA;
2 Department of Surgery, Children's Hospital Boston;
3 Department of Pediatrics, Harvard Medical School, Boston, MA
The anemia of inflammation is an acquired disorder affecting patients with a variety of medical conditions, and it is characterized by changes in iron homeostasis and erythropoiesis. Mounting evidence suggests that hepcidin antimicrobial peptide plays a primary role in the pathogenesis of the anemia of inflammation. To evaluate which features of this anemia can be attributed to hepcidin, we have generated mice carrying a tetracycline-regulated hepcidin transgene. Expression of the hepcidin transgene resulted in down-regulation of endogenous hepcidin mRNA. The transgenic mice developed a mild-to-moderate anemia associated with iron deficiency and iron-restricted erythropoiesis. Similar to the anemia of inflammation, iron accumulated in tissue macrophages, whereas a relative paucity of iron was found in the liver. Circulating erythrocytes in transgenic animals had normal survival rates, but transgenic animals had an impaired response to erythropoietin. Thus, hepcidin transgenic mice recapitulate each of the key features of anemia of inflammation in human patients and serve as a useful model of this prevalent disorder.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
R. T. Means Jr
Ironing out complementary medicine
Blood,
January 8, 2009;
113(2):
270 - 271.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Gardenghi, M. F. Marongiu, K. Muirhead, P. Ramos, C. N. Roy, N. C. Andrews, E. Nemeth, A. Follenzi, E. Rachmilewitz, P. Giardina, et al.
Increased Hepcidin Expression in Mice Affected by {beta}-Thalassemia Reduces Iron Overload with No Effect on Anemia
Blood (ASH Annual Meeting Abstracts),
November 16, 2008;
112(11):
128 - 128.
[Abstract]
|
|
|
|
|
|
|
T. Ganz, G. Olbina, D. Girelli, E. Nemeth, and M. Westerman
Immunoassay for human serum hepcidin
Blood,
November 15, 2008;
112(10):
4292 - 4297.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. C. Andrews
Forging a field: the golden age of iron biology
Blood,
July 15, 2008;
112(2):
219 - 230.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Sharma, E. Nemeth, Y.-H. Chen, J. Goodnough, A. Huston, G.D. Roodman, T. Ganz, and A. Lichtenstein
Involvement of Hepcidin in the Anemia of Multiple Myeloma
Clin. Cancer Res.,
June 1, 2008;
14(11):
3262 - 3267.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Weiss and I. Theurl
Response: Monocyte hepcidin and the anemia of chronic disease
Blood,
April 1, 2008;
111(7):
3902 - 3903.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. D. Fleming
The Regulation of Hepcidin and Its Effects on Systemic and Cellular Iron Metabolism
Hematology,
January 1, 2008;
2008(1):
151 - 158.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. W. Adamson
The Anemia of Inflammation/Malignancy: Mechanisms and Management
Hematology,
January 1, 2008;
2008(1):
159 - 165.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
